[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC

We read with interest the SARAH trial published in The Lancet Oncology.1 Two recently reported randomised controlled trials, the SARAH Trial1 and the SIRveNIb trial,2 were intended to show survival advantages comparing yttrium-90 (90Y) resin microsphere treatment with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Both trials have been negative. We herein discuss the concept that failure to show superiority does not mean 90Y is equivalent to sorafenib, as the conclusion of the SARAH trial might indicate.

Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Josep M Llovet, Richard S Finn Tags: Correspondence Source Type: research